- UPSpace Home
- →
- Health Sciences
- →
- Immunology
- →
- Browsing Immunology by Author
JavaScript is disabled for your browser. Some features of this site may not work without it.
Browsing Immunology by Author "Rapoport, Bernardo Leon"
Now showing items 1-20 of 46
-
Herrstedt, J.; Clark-Snow, R.; Ruhlmann, C.H.; Molassiotis, A.; Olver, I.; Rapoport, Bernardo Leon; Aapro, M.; Dennis, K.; Hesketh, P.J.; Navari, R.M.; Schwartzberg, L.; Affronti, M.L.; Garcia-Del-Barrio, M.A.; Chan, A.; Celio, L.; Chow, R.; Fleury, M.; Gralla, R.J.; Giusti, R.; Jahn, F.; Iihara, H.; Maranzano, E.; Radhakrishnan, Venkatraman; Saito, Mitsue; Sayegh, Paula; Bosnjak, S.; Zhang, L.; Lee, J.; Ostwal, V.; Smit, T.; Zilic, A.; Jordan, Karin; Scotté, F. (Elsevier, 2024-02)Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews ...
-
Rapoport, Bernardo Leon; Herrstedt, Jorn; Snow, Rebecca Clark; Radhakrishnan, Venkatraman; Saito, Mitsue; Navari, Rudolph M.; Smit, Teresa (Springer, 2024-01)PURPOSE : This review is an update of the MASCC/ESMO 2015 recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea ...
-
Olver, Ian; Clark-Snow, Rebecca; Ruhlmann, Christina H.; Garcia-del-Barrio, Maria-Angeles; Schwartzberg, Lee; Rapoport, Bernardo Leon; Jahn, Franziska (Springer, 2024-01)PURPOSE : Review the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and minimal emetic potential. METHODS : A working group performed a ...
-
Blidner, Ada Gabriela; Choi, Jennifer; Cooksley, Tim; Dougan, Michael; Glezerman, Ilya; Ginex, Pamela; Girotra, Monica; Gupta, Dipti; Johnson, Douglas; Shannon, Vickie R.; Suarez-Almazor, Maria; Rapoport, Bernardo Leon; Anderson, Ronald (Springer, 2020-12)Despite the success and ongoing promise of monoclonal antibody–targeted immune checkpoint inhibitor immunotherapy of advanced malignancies, in particular, antibodies directed against CTLA-4 and PD-1/PD-L1, the development ...
-
Retter, Edna; Benn, Carol-Ann; Maske, Christopher; Rapoport, Bernardo Leon (Karger Publishers, 2022-02-07)Angiosarcoma of the breast is an unusual malignancy and carries a poor prognosis, with a 5-year overall survival rate ranging from 27 to 48%. Radiotherapy-induced angiosarcoma (RIAS) of the breast is very uncommon, with ...
-
Theron, Annette J.; Steel, Helen C.; Rapoport, Bernardo Leon; Anderson, Ronald (MDPI Publishing, 2020-11-20)Tumor cells are particularly adept at exploiting the immunosuppressive potential of neutrophils as a strategy to achieve uncontrolled proliferation and spread. Recruitment of neutrophils, particularly those of an immature ...
-
Apalla, Zoe; Rapoport, Bernardo Leon; Sibaud, Vincent (Elsevier, 2021-12)Immune checkpoint inhibitors are a new class of oncologic drugs that act via the inhibition of check- points, thereby unlocking the immune system to attack cancer cells. Their emergence has radically changed the concept ...
-
Rapoport, Bernardo Leon; Steel, Helen C.; Benn, Carol A.; Nayler, Simon; Smit, Teresa; Heyman, Liezl; Theron, Annette J.; Hlatshwayo, Nomsa; Kwofie, Luyanda Laura Illicia; Meyer, P.W.A. (Pieter Willem Adriaan); Anderson, Ronald (Frontiers Media, 2023-03-30)Neoadjuvant chemotherapy (NAC) may alter the immune landscape of patients with early breast cancer (BC), potentially setting the scene for more effective implementation of checkpoint-targeted immunotherapy. This issue ...
-
Rapoport, Bernardo Leon (Frontiers Media, 2019-05-08)Immunotherapy with immune checkpoint inhibitors has emerged as the most significant advance in the treatment of cancer in recent years and has revolutionized cancer management (1). Until recently, it had been assumed ...
-
Kgokolo, C.M.; Anderson, Katherine; Siwele, Shalate C.; Steel, Helen C.; Kwofie, Luyanda Laura Illicia; Sathekge, Mike Machaba; Meyer, Pieter Willem Adriaan; Rapoport, Bernardo Leon; Anderson, Ronald (Frontiers Media S.A., 2022-02-11)Xeroderma Pigmentosum (XP), an autosomal recessive disorder characterized by ultraviolet radiation-induced abnormalities of DNA excision and repair pathways is associated with early development of cutaneous cancers. ...
-
Lipshitz, Melanie; Visser, J.; Anderson, Ronald; Nel, D.G.; Smit, T.G. (Theunis); Steel, Helen C.; Rapoport, Bernardo Leon (Springer, 2023-12)PURPOSE : Emerging biomarkers of cancer cachexia and their roles in sarcopenia and prognosis are poorly understood. Baseline assessments of anthropometrics, sarcopenia, cachexia status and biomarkers of cachexia were ...
-
Jordan, Karin; Chan, Alexandre; Gralla, Richard J.; Jahn, Franziska; Rapoport, Bernardo Leon; Ruhlmann, Christina H.; Sayegh, Paula; Hesketh, Paul J. (Springer, 2024-01)PURPOSE : Our goal was to identify new anticancer agents approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA) since the 2016 MASCC/ESMO antiemetic update and classify their emetic ...
-
Kwofie, Luyanda Laura Illicia; Rapoport, Bernardo Leon; Fickl, Heidi; Meyer, Pieter Willem Adriaan; Rheeder, Paul; Hlope, H.; Anderson, Ronald; Tintinger, Gregory Ronald (Springer, 2012-04)The soluble Triggering Receptor Expressed on Myeloid cells 1 (sTREM-1) is a useful marker of infection in patients with sepsis, but has not been adequately evaluated in patients with chemotherapy-associated febrile ...
-
Rapoport, Bernardo Leon; Aapro, Matti; Paesmans, Marianne; Van Eeden, Ronwyn; Smit, Teresa; Krendyukov, Andriy; Klastersky, Jean (BioMed Central, 2018-09-24)BACKGROUND : Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-stimulating factors (G-CSFs) can significantly reduce the risk of FN. International guidelines recommend G-CSF for ...
-
Gascón, Pere; Harbeck, Nadia; Rapoport, Bernardo Leon; Anderson, Ronald; Brueckmann, Ines; Howe, Sebastian; Aapro, Matti (Elsevier, 2024-04)Filgrastim is approved for several indications, including reduction of the incidence and duration of chemotherapy-induced neutropenia and for stem cell mobilization. The filgrastim biosimilar, EP2006, has been available ...
-
Rapoport, Bernardo Leon; Steel, Helen C.; Theron, Annette J.; Heyman, Liezl; Smit, Teresa; Ramdas, Yastira; Anderson, Ronald (MDPI, 2020-07)High mobility group box 1 (HMGB1) is an extremely versatile protein that is located predominantly in the nucleus of quiescent eukaryotic cells, where it is critically involved in maintaining genomic structure and function. ...
-
Anderson, Ronald; Rapoport, Bernardo Leon (Frontiers Media, 2018-03-22)Realization of the full potential of immune checkpoint inhibitor-targeted oncoimmunotherapy is largely dependent on overcoming the obstacles presented by the resistance of some cancers, as well as on reducing the high ...
-
Anderson, Ronald; Theron, Annette J.; Rapoport, Bernardo Leon (Frontiers Media, 2019-09-26)The advent of novel, innovative, and effective anti-cancer immunotherapies has engendered an era of renewed optimism among cancer specialists and their patients. Foremost among these successful immunotherapies are ...
-
Van Eeden, Ronwyn; Tunmer, Mariza; Geldenhuys, Agneta; Nayler, Simon; Rapoport, Bernardo Leon (Lippincott, Williams & Wilkins, 2020-01)South Africa is the southernmost country in Africa. In 2018, the population of South Africa was estimated at more than 57 million. South Africa is a very diverse and multicultural country that consists of different racial ...
-
Rapoport, Bernardo Leon; Anderson, Ronald; Cooksley, Tim; Johnson, Douglas (Springer, 2020-12)Oncoimmunotherapy with immune checkpoint inhibitor–targeted antibodies has developed as the most significant advance in the management of cancer in recent years. The concept that the immune system was unsuccessful in ...
Now showing items 1-20 of 46